[e-drug] How can we promote rational use of medicines? (5)

E-DRUG: How can we promote rational use of medicines? (5)
---------------------------------------------------

Dear E-Druggers;

in response to Dr Holloway’s request for comments on questions to promote rational use of medicines, I respectfully provide the following:
The definition of rational use of medicines “requires that patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time and at the lowest cost to them and their community”. Implicitly this means that rational use of medicines is to achieve an outcome of health maintenance or improvement in individuals and in the community in a sustainable manner. Logically therefore, the purpose of the whole supply chain management sector is to achieve rational use of essential good quality medicines for a safe health maintenance or improvement outcome. To facilitate understanding for planning and implementing interventions to promote rational use of medicines therefore requires an analysis of poor or unsafe procedures at all stages of the medical supplies management sector, as compared to a limited approach to improve prescription of and consumer use of those medicines.

There is no shortage of data from developed and developing countries, that
provides detail of non-rational practices in the (mis) management of the
medicines sector, including examples of poor quality of manufacture, increased counterfeiting, selection of products un- related to reducing disease burden, inefficient procurement, poor quality of storage, ineffective and/or inappropriate distribution, questionable prescription, unprofessional dispensing, unethical marketing practices, lack of security and unhealthy consumption of medicines practices. The data are possible indicators that senior health systems managers in government, the professions, and community are only partially convinced about the specific management requirements for medicines (and medical supplies) that are vital to result in their safe and rational use for health improvement. This lack of conviction, can in turn lead to a prevailing indifference to the potential for global adverse public health outcomes that can and do result from non-rational management and poor use of medicines practices.

It is important to determine the risks that hinder rational use of medicines. The risks are certainly not limited to poor prescription and poor use of medicines by consumers. Indeed so many potent medicines including anti-infective agents are not “prescribed” by competent authorised persons but are freely available and sold by unskilled retailers. There are different examples where consumer use of medicines are more rational than what is “prescribed”.
Other factors that directly or indirectly adversely affect the achievement of rational use of medicines are limitations in, or absence of appropriate
country specific policies, laws or enforcement of the law, inadequate health care education or non-disciplined behaviour by key stakeholders
(administrators, practitioners and consumers) in medical supply chain
management. Rational medicines use is severely compromised wherever there is not collective acceptance or support for the unique and disciplined management practices required to assure the human right for access to good quality essential medicines and professional support for effective use of that medicine. The protection of this human right requires a disciplined sectoral focus by government and health care professionals, to establish and enforce local specific minimum standards for medical supply management infrastructure, human resources and systems that do result in overall safe and rational behaviour in the management of medicines for a healthy outcome.

Phillip Passmore PhD;
Manager ANTARA Medical Supplies Management Sub-program;
NTT Province Indonesia.
Adjunct Senior Lecturer, Curtin University of
Technology, School of Pharmacy Western Australia.
psmint@iinet.net.au

E-DRUG: How can we promote rational use of medicines? (8)
-----------------------------------------------

Dear E-Druggers,

While this discussion on the rational use of medicines goes on, the
pharmaceutical industry is mounting a European-wide campaign to pressure
countries and the EU to increase spending on cancer drugs. See today's
article in The Guardian. Go to www.guardian.co.uk. The campaign appears to feature pseudo-grassroots organizations, biased research, and misleading
information.

The underlying theme of European campaigns overall seems to be:

The More Medicines You Take, The Healthier You Will Be.

See, for example, the Bain report alleging that Germans are sicker than
Americans because they take fewer drugs.

Donald Light
Princeton University
USA
dlight@princeton.edu

E-DRUG: How can we promote rational use of medicines? (9)
-----------------------------------------------

Dear E-Druggers,

Pakistan; in a move to check on spurious medicines the
two member bench at the supreme court of Pakistan
directed federal health secretary "to ensure
compliance with a legal requirement according to which
presence of a licensed pharmacist is must at each and
every drug store".

This should also be expanded to each and every
hospital. By emphasizing the role of pharmacist who is
the last check point in the health care system can be
a step forward in promoting RDU.

Azhar Hussian
Director (Associate Professor)
Hamdard Institute of Pharmaceutical Sciences
Hamdard University, F-8 Markaz
Islamabad, Pakistan.
Tel:00-92-51-2856901 EXt-217
Fax:00-92-51-2856403
azhar_26@yahoo.com

E-DRUG: Availability of Modern Cell Culture Rabies Vaccine
----------------------------------------------------------

Dear All,
   
  According to WHO, more than three billion people are at risk for rabies in over 85 countries and territories worldwide, and about 50,000–60,000 human deaths from rabies are estimated to occur annually, even though effective vaccines for postexposure prophylaxis (PEP) are available and over 10 million individuals actually receive rabies PEP each year. PEP therapy has become safe and virtually painless due to the availability modern cell culture vaccine recently. Unfortunately in developing countries including india modern cell culture vaccine therapy is not economical to majority of the victims and therefore receiving unsafe nerve tissue vaccine (NTV) produced from rabies virus infected sheep brain tissue.
   
  Recently In India also many public sector companies discontinued the production of nerve tissue vaccine to phase out nerve tissue vaccine following the recommendations from WHO due to adverse reactions. Only Three companies are producing modern cell culture rabies vaccine. They are not increased their capacities to meets the demand in view of phase out of nerve tissue vaccine.

  Many rabies treatment centres are have been reeling under acute shortage of modern cell culture rabies vaccine for the last couple of months.
   
  To solve this problem Indian government has been introduced Intradermal therapy for post exposure rabies therapy, which requires less vaccine. Eventhough many rabies treatment centres are facing acute shortage of rabies vaccine.
   
  In this contrast, I would like to know the situation of rabies vaccine availability in developing countries in view of recommendation by WHO to phase out nerve tissue vaccines by December 2006. Are there any country still producing nerve tissue vaccine?
   
Thanking you.
   
Dr.Dharmesh Mehata M.B.B.S
Jaipur, Rajistan, India
dharmeshmehata@yahoo.co.in